{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:15:02Z","timestamp":1786400102449,"version":"build-2736575974"},"reference-count":49,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Adv"],"published-print":{"date-parts":[[2018,7,10]]},"DOI":"10.1182\/bloodadvances.2017015545","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T15:59:43Z","timestamp":1531238383000},"page":"1633-1644","source":"Crossref","is-referenced-by-count":79,"title":["Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials"],"prefix":"10.1182","volume":"2","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Banchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Groarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhee","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim S.","family":"Iskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"2018071008593649000_2.13.1633.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530440037034"},{"key":"2018071008593649000_2.13.1633.2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440150033003"},{"key":"2018071008593649000_2.13.1633.3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.131"},{"key":"2018071008593649000_2.13.1633.4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12231212"},{"issue":"5","key":"2018071008593649000_2.13.1633.5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.ackd.2012.06.001","article-title":"Current approach to diagnosis and management of acute renal failure in myeloma patients","volume":"19","author":"Leung","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"issue":"suppl 3","key":"2018071008593649000_2.13.1633.6","first-page":"24","article-title":"Overview and management of cardiac and pulmonary adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib","volume":"27","author":"Wang","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"21","key":"2018071008593649000_2.13.1633.7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2916.2916","article-title":"Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice","volume":"120","author":"Kistler","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2018071008593649000_2.13.1633.8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1186\/s12885-016-2955-0","article-title":"Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study","volume":"16","author":"Chari","year":"2016","journal-title":"BMC Cancer"},{"key":"2018071008593649000_2.13.1633.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"2018071008593649000_2.13.1633.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"issue":"10","key":"2018071008593649000_2.13.1633.11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"2018071008593649000_2.13.1633.12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/leu.2017.122","article-title":"Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes","volume":"31","author":"Hari","year":"2017","journal-title":"Leukemia"},{"key":"2018071008593649000_2.13.1633.13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"2018071008593649000_2.13.1633.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755"},{"key":"2018071008593649000_2.13.1633.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"issue":"3","key":"2018071008593649000_2.13.1633.16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"2018071008593649000_2.13.1633.17","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1080\/10428194.2017.1298755","article-title":"Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup","volume":"58","author":"Ludwig","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2018071008593649000_2.13.1633.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0822"},{"key":"2018071008593649000_2.13.1633.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3007"},{"key":"2018071008593649000_2.13.1633.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3352"},{"key":"2018071008593649000_2.13.1633.21","doi-asserted-by":"crossref","unstructured":"Jones SF , Bendell JC , Burris HA , . Effects of carfilzomib (CFZ) on pharmacokinetics of midazolam (MDZ) in subjects with solid tumors. In: Proceedings from American Association for Cancer Research 102nd Annual Meeting; 2-6 April 2011; Orlando, FL. Abstract 1298.","DOI":"10.1158\/1538-7445.AM2011-1298"},{"key":"2018071008593649000_2.13.1633.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.08.003"},{"key":"2018071008593649000_2.13.1633.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"2018071008593649000_2.13.1633.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"2018071008593649000_2.13.1633.25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"issue":"1","key":"2018071008593649000_2.13.1633.26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"2018071008593649000_2.13.1633.27","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Bethesda, MD: National Cancer Institute; 2010. NIH Publication no. 09-5410."},{"key":"2018071008593649000_2.13.1633.28","doi-asserted-by":"crossref","unstructured":"Stewart A , Siegel D , Ludwig H , . Overall survival (OS) of patients with relapsed\/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): final analysis from the randomized phase 3 ASPIRE trial [abstract]. Blood. 2017;130(suppl 1). Abstract 743.","DOI":"10.1182\/blood.V130.Suppl_1.743.743"},{"key":"2018071008593649000_2.13.1633.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556308"},{"issue":"15 suppl","key":"2018071008593649000_2.13.1633.30","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2017.35.15_suppl.8018","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"35","author":"Waxman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2018071008593649000_2.13.1633.31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93"},{"key":"2018071008593649000_2.13.1633.32","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12677"},{"key":"2018071008593649000_2.13.1633.33","doi-asserted-by":"crossref","unstructured":"Chari A , Aggarwal SK , Mezzi K , . Cardiac events in real-world multiple myeloma patients treated with carfilzomib: a retrospective claims database analysis [abstract]. Blood. 2016;128(22). Abstract 3319.","DOI":"10.1182\/blood.V128.22.3319.3319"},{"key":"2018071008593649000_2.13.1633.34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"issue":"5-6","key":"2018071008593649000_2.13.1633.35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000448757","article-title":"Bortezomib effects on human microvascular endothelium in vitro","volume":"98","author":"Sahni","year":"2016","journal-title":"Pharmacology"},{"issue":"1","key":"2018071008593649000_2.13.1633.36","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J"},{"key":"2018071008593649000_2.13.1633.37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-915"},{"issue":"5","key":"2018071008593649000_2.13.1633.38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jcph.850","article-title":"Population pharmacokinetics and exposure-response relationship of carfilzomib in patients with multiple myeloma","volume":"57","author":"Ou","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2018071008593649000_2.13.1633.39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003269"},{"key":"2018071008593649000_2.13.1633.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.01.008"},{"issue":"10","key":"2018071008593649000_2.13.1633.41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10245332.2017.1328165","article-title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies","volume":"22","author":"Jakubowiak","year":"2017","journal-title":"Hematology"},{"key":"2018071008593649000_2.13.1633.42","first-page":"1","article-title":"Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity","volume":"8","author":"Lendvai","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2018071008593649000_2.13.1633.43","first-page":"1855","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"130","author":"Cornell","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2018071008593649000_2.13.1633.44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11906-014-0447-7","article-title":"Hypertension as a risk factor for heart failure","volume":"16","author":"Kannan","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"2018071008593649000_2.13.1633.45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/erc.09.8","article-title":"Management of hypertension in chronic heart failure","volume":"7","author":"Manickavasagam","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"2018071008593649000_2.13.1633.46","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/clc.20627","article-title":"Symptom presentation in patients hospitalized with acute heart failure","volume":"33","author":"Goldberg","year":"2010","journal-title":"Clin Cardiol"},{"key":"2018071008593649000_2.13.1633.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.11.008"},{"key":"2018071008593649000_2.13.1633.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.02.005"},{"key":"2018071008593649000_2.13.1633.49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3522"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1182\/bloodadvances.2017015545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T05:13:25Z","timestamp":1661577205000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.bloodadvances.org\/lookup\/doi\/10.1182\/bloodadvances.2017015545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":49,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2018,7,10]]},"published-print":{"date-parts":[[2018,7,10]]}},"alternative-id":["10.1182\/bloodadvances.2017015545"],"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017015545","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]}}}